Latest News
Revolutionizing FinTech: An Exclusive Conversation with Tīna Lūse, Attorney-at-Law and Leader of the Fintech Latvia Association
Welcome to our latest edition where we delve deep into the thriving world of FinTech in Latvia. Today, we’re privileged to have an exclusive interview with a person at the forefront of this rapidly evolving sector – Tīna Lūse. As an accomplished Attorney-at-Law and the current Head of the Fintech Latvia Association, Tīna provides unique insights into the burgeoning Latvian FinTech scene. From regulatory challenges to the influence of emerging technologies, she’ll share her expert viewpoint on the current state and future potential of Latvia’s FinTech industry. Stay tuned as we embark on this fascinating journey, discovering what makes Latvia a dynamic player in the global FinTech landscape.
Tīna Lūse – Attorney-at-Law, Head of the Fintech Latvia Association
Since January 2021, Tīna leads the Fintech Latvia Association. The aim of the Association is to unite the providers of financial services of the non-banking sector based on financial technologies in order to ensure the representation and implementation of their interests at the national and international level, promoting sustainable development and growth of the Latvian financial sector.
TFB: What strategies should regulatory bodies employ to delve deeper into FinTech solutions?
TL: The formula is the same as with everything else: if one wants to learn and improve something, one must become very curious about it. The same goes for better understanding the fintech – communication with the sector players is the key. Only through communication and cooperation is it possible to gain understanding and knowledge about what the sector offers and also what risks it really brings along. Open communication, attending industry-related events, conferences, and discussion forums is the way to gain knowledge and take away prejudice. The sector players have also always stressed the importance of cooperation and harvesting from the intelligence that the fintech sector can offer to improve public sector operations as well. As an association, we are contributing to this process by organizing our series of networking and discussion events -Fintech Breakfast, where we are bringing together private fintech players with the policymakers and regulators to delve into various topics that are of importance to the development of fintech. And it makes me happy that I do not have to be diplomatic when I am saying that we see a great response and interest to better the development of this sector both from the Ministry of Finance and the Bank of Latvia, which are the 2 key players for the sector because it is simply an honest truth at the moment in Latvia.
TFB: How are government agencies reorganizing their structures to accommodate FinTech?
TL: We see that the Bank of Latvia, which is the central licensing and supervisory authority for fintechs in Latvia, has really done its homework in reviewing the licensing processes and is nowadays referred to as another fintech just from the public sector by the market players. There will always be room for improvement, but at the moment they are quite praised by the market players and consultants for being very responsive, willing to cooperate, and understand new and innovative business models. Even though we still hear that speed could sometimes be improved, nevertheless the first EU-wide crowdfunding license under ECSP Regulation was issued in a mere 3 months time after submission of the application. And it is all possible because of special consultancy and sandbox regimes that are set up to enable the companies that are planning to enter the market to have a good quality pre-licensing consultations and a ground for testing innovative products and their compliance with the regulatory environment. Reliable support from the consultants is also of great importance. And we have all this ecosystem in place at the moment.
TFB: Which organizational leaders should spearhead fintech initiatives and why?
TL: It must be a team effort. A team consisting of policymakers: Ministry of Finance, Ministry of Economics, and in some parts also the Ministry of Education, regulators: Bank of Latvia and also Consumer Rights Protection Center, and, of course, fintech market players. And it must be understood that maintaining and contributing to such dialogue with the public sector takes quite a lengthy and regular investment of time, which is normal, because, as they say, “Rome wasn’t built in a day”. And of course, we all know that running a business, and especially building something new and innovative requires a lot of time on its own. But I think it is important for any business to understand that devoting a resource and time to build a good quality dialogue with the public sector is equally important as onboarding and providing an excellent service level to customers.
TFB: In what ways can financial regulators harness data to enhance their operations?
TL: To understand where to focus their attention and spend resources, so to say, to understand the “value for money” ratio for their activities. To understand, some active steps and support mechanisms from the state are needed to foster development. To assess the impact of certain services on a broader society and calibrate the supervisory activities accordingly.
TFB: What are the greatest opportunities and challenges related to financial data for public regulatory bodies?
TL: I think the opportunities are what was described above. If we come to challenges then as with any other industry the greatest challenge is to get good quality data, because it requires some level of planning and coordination between different public and private actors. The next challenge is to understand how to interpret the data and after the data is there to not fall into the temptation of overregulation, which, of course, will bring any development and innovation to a halt.
TFB: Can you share some significant achievements that organizations have made so far in the FinTech space?
TL: Already more than 10 years back we saw our first fintech in the consumer lending sector, which brought about a lot of controversy and at times did not let us appreciate the financial inclusion aspect that the service is offering. Now the strongest of those companies, such as 4finance, and Eleving group, have turned into mature international players that are contributing to the financial literacy of the society and the development of new and more accessible financial products.
What we are all proud of without the controversy attached is our investment platforms, Mintos being the most recognizable name among those. But there are more: Twino, VIA Invest, Nectaro, InDemo, and Debitum, just to name a few. Crowded Heroe and Lande – crowdfunding platforms, which are not only offering good investment opportunities to investors but also financing to SMEs that are not typical bank clients.
Nordigen – the first free open banking data provider in Europe is also coming from Latvia.
TFB: How can we address and overcome the challenges related to skills and mindset that hinder FinTech adoption?
TL: By learning and understanding. One of the main challenges when it comes to fintech is the fear of the unknown, and as we know, it can only be overcome by understanding. And here the dialogue that I mentioned earlier is key.
We’re also excited to share that Tīna Lūse was a key speaker at this year’s MARE BALTICUM Gaming & TECH Summit held in Riga. Her presentation, packed with insights and in-depth analysis, was indeed one of the highlights of the summit. For those of you who missed this year’s event or are eager for the next, we have great news! You can now pre-register for the 2024 edition of the MARE BALTICUM Gaming & TECH Summit. Mark your calendars for May 13-15 as we head to Tallinn, Estonia for another round of inspiring talks, engaging panel discussions, and fantastic networking opportunities. Don’t miss your chance to be part of this significant industry event. Secure your spot now!
Latest News
Sweden’s Mitigram names Pedram Tadayon as new CEO
Latest News
Egypt’s Swypex launches an all-in-one fintech platform after $4m seed round
Swypex, an Egyptian startup, has unveiled its comprehensive financial services platform for businesses after securing a $4 million seed investment round led by the prestigious venture capital fund, Accel.
Co-founded by Ahmad Mokhtar, Tarek Mokhtar, and Sasan Hezarkhani, and licensed by the Central Bank of Egypt, Swypex offers an all-in-one financial management platform. This platform equips businesses with instant access to a financial dashboard, smart corporate cards, and seamless integrations with existing financial systems and accounting software.
Positioning itself as the first of its kind, Swypex aims to eradicate financial inefficiencies and maximize a business’s potential. By consolidating payments, invoice management, and smart corporate cards on a unified platform, Swypex simplifies financial management, enabling businesses to automate workflows and facilitate payments effortlessly.
The platform’s launch is backed by a $4 million seed round, led by global venture capital firm Accel, marking its inaugural fintech investment in the region. The funding round also saw participation from Foundation Ventures, The Raba Partnership, and notable angel investors.
Ahmad Mokhtar, CEO of Swypex, emphasized the company’s mission to provide Egyptian businesses with a competitive edge, enhancing efficiency and fostering growth. He highlighted Swypex’s commitment to streamlining financial operations and enhancing financial health by offering robust corporate cards paired with an all-in-one financial platform.
Richard Kotite, vice president at Accel, underscored the significance of delivering modern fintech products to Egyptian businesses amid the ongoing digitization of the payments space. He commended Swypex for identifying a market gap and developing a comprehensive B2B solution to address key pain points while driving efficiency.
Accel recognizes Swypex’s potential to emerge as a fintech leader in the Middle East, citing the team’s technical expertise and ambition. The partnership between Accel and Swypex signifies a significant leap forward in revolutionizing financial services in the region.
Source: disruptafrica.com
The post Egypt’s Swypex launches an all-in-one fintech platform after $4m seed round appeared first on HIPTHER Alerts.
Latest News
Piramal Pharma Limited Announces Results for Q4 and FY2024
MUMBAI, India, May 10, 2024 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full Year (FY) ended 31st March 2024.
Consolidated Financial Highlights |
||||||
(In INR Crores) |
||||||
Particulars |
Q4 FY24 |
Q4 FY23 |
YoY Growth |
FY24
|
FY23
|
YoY Growth |
Revenue from Operations |
2,552 |
2,164 |
18 % |
8,171 |
7,082 |
15 % |
CDMO |
1,649 |
1,281 |
29 % |
4,750 |
4,001 |
19 % |
Complex Hospital Generic (CHG) |
667 |
702 |
(5) % |
2,449 |
2,286 |
7 % |
India Consumer Healthcare (ICH) |
238 |
210 |
14 % |
985 |
874 |
13 % |
EBITDA# |
556 |
376 |
48 % |
1,372 |
853 |
61 % |
EBITDA Margin |
22 % |
17 % |
17 % |
12 % |
||
PAT (before exceptional item) |
132 |
50 |
163 % |
81 |
(180) |
NA |
Exceptional Item* |
(31) |
0 |
NA |
(63) |
(7) |
NA |
PAT (after exceptional item) |
101 |
50 |
102 % |
18 |
(186) |
NA |
# FY2023 EBITDA had one-time inventory margin impact of INR 68 Crores |
||||||
* Q4 FY24 Exceptional item of INR 31 Crores towards non-cash write down of investment and license rights in relation to a certain third-party |
Key Highlights for Q4 and FY2024
- Revenue from Operations grew by 18% YoY and 15% YoY in Q4FY24 and FY24 respectively, driven by healthy growth in our CDMO and ICH businesses
- EBITDA grew by 48% YoY and 61% YoY in Q4FY24 and FY24 respectively, primarily driven by revenue growth, operating leverage, cost optimization, and operational excellence initiatives
- Net Profit After Tax (before exceptional Items) more than doubled in Q4FY24 at INR 132 Crores compared to INR 50 Crores in Q4FY23
- Net Debt / EBITDA improved from 5.6x at the start of the financial year to 2.9x at the end of FY24
Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY24 has been a strong year for the Company with all round improvement, mainly driven by our CDMO business that delivered a robust 19% YoY revenue growth. We saw significant increase in order inflows, especially for on-patent commercial manufacturing, amidst a difficult biotech funding environment. Contributions from our innovation related work and differentiated offerings also increased in FY24. Capacity expansion at our Grangemouth facility for Antibody Drug Conjugate segment was commercialized and is seeing good customer interest.
In the Inhalation anesthesia business, we continue to maintain our leading position in Sevoflurane in the US market and are expanding our capacities to tap the growing demand in the ROW markets. Our India Consumer Healthcare business is also continuing to perform well with focus on better EBITDA margin.
During the year, we also showed a significant improvement in our profitability with EBITDA margin of 17% (Vs. 12% in FY23). All our three businesses delivered higher EBITDA margins through operating leverage, cost optimization, and operational excellence initiatives. Our Net Debt / EBITDA ratio also improved significantly, as we ended the financial year below 3x compared to 5.6x at the start of the year.”
Key Business Highlights for Q4FY24 and FY24 |
Contract Development and Manufacturing Organization (CDMO): – Strong Order Inflows: Despite challenging biotech funding environment, our new service order# inflows in FY24 were significantly higher compared to FY23, especially for commercial manufacturing of on-patent molecules – Innovation Related Work: Our share of CDMO revenues from Innovation related work increased from 45% in FY23 to 50% in FY24 – On-patent Commercial Manufacturing: Revenue from commercial manufacturing of on-patent molecules more than doubled to $116mn in FY24 compared to $52mn in FY23 – Differentiated Offerings: Revenue contribution from differentiated offerings increased from 37% in FY23 to 44% in FY24 – Integrated Projects: Over 40% of the service order book in FY24 was from integrated projects, highlighting customer preference for integrated service offerings – Improved Profitability in our CDMO business driven by revenue growth, favorable revenue mix, normalization of raw material cost and cost optimization initiatives – Best-in-class quality track record – Successfully cleared 36 regulatory inspections and over 170 customer audits in FY24
Complex Hospital Generics: – Strong Volume Growth: Witnessed strong volume growth in our inhalation anesthesia portfolio in the US and ROW markets, partly offset by lower market prices – Maintained our #1 Rank* in the US in terms of value market share in Sevoflurane. Also continue to be the leading company in intrathecal Baclofen in the US market – Expanding our capacities to meeting growing demand of Inhalation anesthesia products in the ROW markets. Also focus on improving output through greater operating efficiencies – Improved profitability in our CHG business during FY24 mainly led by cost optimization initiatives, yield improvement and better product and market mix – New Product Pipeline: Launched 4 new injectable products in FY24 in the US and Europe. Building a pipeline of 24 new products which are at various stages of development with current addressable market size of over $2bn
India Consumer Healthcare: – Power Brands comprising of Lacto Calamine, Littles, Polycrol, Tetmosol and I-range, registered YoY growth of 15% during Q4FY24 and 13% during FY24 – New Product Launches: 27 new products and 24 new SKUs launched during FY24. Over 150 new products and SKUs launched in the last three years – Improved EBITDA margin in FY24 driven by operating leverage – Promotional spends during FY24 was at 13% of ICH revenue vs 15% in FY23 – E-commerce grew at about 36% YoY in FY24, contributing 20% to ICH revenue. Presence across 20+ e-commerce platforms including own direct-to-customer website -Wellify.in #New development and commercial orders. These are over and above the existing multi-year manufacturing relationships *Source: IQVIA data |
Consolidated Profit and Loss Statement |
||||||||
(In INR Crores) |
||||||||
Reported Financials |
||||||||
Particulars |
Quarterly |
Full Year |
||||||
Q4FY24 |
Q4FY23 |
YoY Change |
Q3FY24 |
QoQ |
FY24 |
FY23 |
YoY Change |
|
Revenue from Operations |
2,552 |
2,164 |
18 % |
1,959 |
30 % |
8,171 |
7,082 |
15 % |
Other Income |
26 |
25 |
8 % |
62 |
(57) % |
175 |
225 |
(22) % |
Total Income |
2,579 |
2,188 |
18 % |
2,020 |
28 % |
8,347 |
7,307 |
14 % |
Material Cost |
1,014 |
840 |
21 % |
675 |
50 % |
2,954 |
2,703 |
9 % |
Employee Expenses |
494 |
474 |
4 % |
524 |
(6) % |
2,030 |
1,896 |
7 % |
Other Expenses |
514 |
499 |
3 % |
491 |
5 % |
1,991 |
1,854 |
7 % |
EBITDA# |
556 |
376 |
48 % |
330 |
69 % |
1,372 |
853 |
61 % |
Interest Expenses |
114 |
104 |
10 % |
106 |
8 % |
448 |
344 |
30 % |
Depreciation |
196 |
184 |
6 % |
186 |
5 % |
741 |
677 |
9 % |
Profit Before Tax |
246 |
87 |
182 % |
38 |
553 % |
183 |
(168) |
NA |
Tax |
126 |
45 |
182 % |
9 |
1,264 % |
161 |
66 |
144 % |
Share of net profit of associates |
12 |
8 |
55 % |
14 |
(14) % |
59 |
54 |
9 % |
Net Profit after Tax (before exceptional item) |
132 |
50 |
163 % |
42 |
211 % |
81 |
(180) |
NA |
Exceptional item* |
(31) |
0 |
NA |
(32) |
NA |
(63) |
(7) |
NA |
Net Profit after Tax (after exceptional item) |
101 |
50 |
102 % |
10 |
902 % |
18 |
(186) |
NA |
# FY23 EBITDA had one-time inventory margin impact of INR 68 Crore |
||||||||
*Q3FY24 – Related to non-recurring charges towards product recall triggered by a third-party supplier; Q4FY24 – Towards non-cash write |
Consolidated Balance Sheet |
||
(In INR Crores) |
||
Key Balance Sheet Items |
As at |
|
31-Mar-24 |
31-Mar-23 |
|
Total Equity |
7,911 |
6,774 |
Net Debt |
3,932 |
4,781 |
Total |
11,843 |
11,555 |
Net Fixed Assets |
9,106 |
8,887 |
Tangible Assets |
4,250 |
3,589 |
Intangible Assets including goodwill |
3,740 |
3,880 |
CWIP (including IAUD*) |
1,116 |
1,419 |
Net Working Capital |
2,339 |
2,307 |
Other Assets# |
398 |
361 |
Total Assets |
11,843 |
11,555 |
*IAUD – Intangible Assets Under Development |
||
# Other Assets include Investments and Deferred Tax Assets (Net) |
Q4 and FY2024 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 13th May 2024 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY2024 Results.
The dial-in details for the call are as under:
Event |
Location & Time |
Telephone Number |
Conference call on |
India – 09:30 AM IST |
+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
1 800 120 1221 (Toll free number) |
||
USA – 12:00 AM (Eastern Time – New York) |
Toll free number 18667462133 |
|
UK – 05:00 AM (London Time) |
Toll free number 08081011573 |
|
Singapore – 12:00 PM (Singapore Time) |
Toll free number 8001012045 |
|
Hong Kong – 12:00 PM (Hong Kong Time) |
Toll free number 800964448 |
|
Express Join with Diamond Pass™ |
Please use this link for prior registration to reduce wait time at the time of joining the call –https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9765638&linkSecurityString=3bb8d8359c |
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL’s associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: https://www.piramalpharma.com/, Facebook, Twitter, LinkedIn
Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2024-302142540.html
-
Latest News5 days ago
The General Assembly of Siniora Food Industries Company approved the distribution of cash dividends amounting to JD 4.2 million representing 15% of its paid-in capital, and stock dividends amounting to 2,147,059 shares
-
Latest News5 days ago
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
-
Latest News5 days ago
IRIS Business Services Introduces “IRIS Myeinvois” SaaS Platform for Seamless e-Invoice Compliance in Malaysia
-
Latest News4 days ago
Top 10 Sessions You Can’t Miss at MARE BALTICUM Gaming & TECH Summit 2024 (Tallinn, Estonia, 4-5 June)
-
Latest News5 days ago
Halal Economy Leadership Forum 2024 Riyadh: IsDB, HPDC and HDC’s Collaboration to Spearhead Innovation for Global Halal Industry
-
Latest News4 days ago
Tiger Brokers (HK) officially launches virtual asset trading services, leading the way in Hong Kong’s online brokerage industry
-
Latest News3 days ago
Mashreq Partners with Silent Eight for Compliance Alert Adjudication
-
Latest News4 days ago
ICEYE Announces API That Allows Customers to Directly Task World’s Largest SAR Satellite Constellation